‘First-in-Human’ Drug for Malignant Glioma Available in Experimental Trial

Man poses for picture

Cincinnati—The UC Cancer Institute is one of three centers internationally approved to test an experimental drug’s safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.

The “first-in-human” phase-1 trial is expected to enroll up to 60 patients at clinical sites in the United States and Australia. It will include patients treated at the UC Brain Tumor Center.

Led by Olivier Rixe, MD, PhD, this experimental drug trial uses antibody-drug conjugate (ADC) technology, a new drug delivery concept currently being investigated in the treatment of various cancers. ADC molecules consist of an antibody linked to a specific cytotoxic drug that is intended to target, bind and disperse only in malignant cells.

Learn more >>

This entry was posted in Articles. Bookmark the permalink. Both comments and trackbacks are currently closed.

Click Here to learn about our most recent updates, visitor restrictions, testing, safety precautions and more.